| Title |
Bevacizumab plus chemotherapy as salvage treatment in chemorefractory patients with metastatic colorectal cancer
|
|---|---|
| Published in |
OncoTargets and therapy, January 2013
|
| DOI | 10.2147/ott.s41383 |
| Pubmed ID | |
| Authors |
Ravit Geva, Loredana Vecchione, Sabine Tejpar, Hubert Piessevaux, Eric Van Cutsem, Hans Prenen |
| Abstract |
The combination of chemotherapy and bevacizumab, a monoclonal antibody targeting the vascular endothelial growth factor, is consistently being used as first- and second-line treatment in patients with metastatic colorectal cancer (mCRC). There is little data of the activity of bevacizumab in chemorefractory mCRC patients. The aim of this retrospective single center study was to evaluate the activity of bevacizumab combined with chemotherapy in this study population. |
X Demographics
The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 3 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 67% |
| Practitioners (doctors, other healthcare professionals) | 1 | 33% |
Mendeley readers
The data shown below were compiled from readership statistics for 25 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 25 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Other | 5 | 20% |
| Professor | 3 | 12% |
| Student > Bachelor | 2 | 8% |
| Student > Doctoral Student | 2 | 8% |
| Student > Ph. D. Student | 2 | 8% |
| Other | 7 | 28% |
| Unknown | 4 | 16% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 17 | 68% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 8% |
| Computer Science | 1 | 4% |
| Unknown | 5 | 20% |
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 05 February 2013.
All research outputs
#15,879,822
of 25,584,565 outputs
Outputs from OncoTargets and therapy
#839
of 2,967 outputs
Outputs of similar age
#178,462
of 289,948 outputs
Outputs of similar age from OncoTargets and therapy
#5
of 13 outputs
Altmetric has tracked 25,584,565 research outputs across all sources so far. This one is in the 36th percentile – i.e., 36% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,967 research outputs from this source. They receive a mean Attention Score of 3.0. This one has gotten more attention than average, scoring higher than 70% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 289,948 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 37th percentile – i.e., 37% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 13 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 69% of its contemporaries.